All Categories >
Anti-Payload—MMAE/MMAF Antibody
Antibody–drug conjugates (ADCs) are an emerging class of targeted therapies for cancer treatment, designed to deliver cytotoxic small-molecule payloads directly to and kill tumor cells. Essentially a form of targeted chemotherapy, ADCs have now advanced to the third generation, with substantial improvements in both safety and efficacy. Technological innovations in this field have primarily focused on the payload, the linker, and the conjugation methodology, while the engineering and optimization of the payload remain a central focus for enhancing ADC performance.
Learn more+
Antibody–drug conjugates (ADCs) are a class of promising biologic therapeutics designed to selectively deliver highly cytotoxic payloads to tumor cells while sparing normal tissues. They can be regarded as prodrugs that remain stable in the bloodstream, minimizing drug release during circulation and enabling efficient conversion to the active form at the tumor site. Designing the optimal tripartite combination of monoclonal antibody (mAb), linker, and payload requires careful monitoring and understanding of the physicochemical properties of these three components in both the systemic circulation and the tumor microenvironment. In particular, the linker plays a critical role in determining the potency and safety profile of the ADC; therefore, in vivo assessment of “drug–linker stability” is essential for guiding linker selection, which is typically achieved through the determination of pharmacokinetic (PK) parameters.
Learn more+
IFN-γ Enzyme-Linked Immunospot Assay Kit (ELISPOT)
Enzyme-linked immunospot assay: The term “enzyme-linked” carries the same meaning as in ELISA, referring to an immunoassay that relies on enzymatic reaction amplification. As with ELISA, the antibodies in ELISPOT are immobilized (coated) onto a solid support; however, whereas ELISA antibodies capture target proteins that are already present and uniformly distributed in the sample solution, ELISPOT antibodies capture proteins freshly secreted by cells in response to dynamic stimulation. In ELISA, the detection signal is manifested as a colored solution, whereas in ELISPOT it appears as colored spots deposited on the solid substrate. Both ELISPOT and ELISA are based on the sandwich immunoassay principle, but ELISPOT further incorporates cell culture techniques. While ELISA provides quantitative measurement of the concentration of a target protein in the sample solution, ELISPOT offers a dynamic assessment of the immune status of live cells within the sample.
Learn more+
In the research, development, and manufacturing of CAR-T products, the CAR expression rate is a critical research parameter and performance indicator that is integral throughout preclinical studies, process development, and product quality control, and it also serves as an excellent companion diagnostic marker in subsequent clinical trials.
Learn more+
General PK assay antibodies for scFv, BsAb, etc. (including G4S linker)
Last year, Hycells launched its blockbuster, universal CAR positivity assay antibody—Anti-G4S linker—which quickly won widespread recognition and collaboration from a growing customer base thanks to its ease of use and high precision. Anti-G4S linker is a universally applicable CAR positivity assay reagent that has been rigorously validated by numerous customers; by eliminating unnecessary and time-consuming steps, it accelerates the drug development process. It is suitable for detecting CARs with G4S linkers targeting any antigen ((G4S)n, where n ≥ 2), as well as for assays involving various antibody types that incorporate (G4S)n (where n ≥ 2). Moreover, it exhibits robust resistance to interference, remaining unaffected by antigen cross-reactivity and delivering more accurate in vivo CAR proportion measurements. Its exceptional sensitivity ensures outstanding detection performance even at very high or very low concentrations.
Learn more+
New Reagent for Detecting the CAR Positive Rate of Anti-(G4S)n (B02H1) Monoclonal Antibody
A CAR is an engineered receptor designed to modulate and redirect immune cell responses toward tumor-associated antigens of intrinsic origin. This receptor is a chimeric protein composed of four principal components: an extracellular antigen-binding domain (e.g., a single-chain variable fragment or scFv), a spacer or hinge domain, a transmembrane domain, and at least one intracellular signaling domain. The successful integration of these components enables CAR-expressing immune cells to recognize specific antigens and kill tumor cells.
Learn more+
